Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

被引：151

作者：

Szarek, Michael ^{[1
,1411
]}

White, Harvey D. ^{[2
,63
,1407
]}

Schwartz, Gregory G. ^{[3
]}

Alings, Marco ^{[4
]}

Bhatt, Deepak L. ^{[5
,6
]}

Bittner, Vera A. ^{[7
]}

Diaz, Rafael ^{[10
,30
,1405
]}

Edelberg, Jay M. ^{[11
]}

Goodman, Shaun G. ^{[12
,13
]}

Hanotin, Corinne ^{[14
]}

Harrington, Robert A. ^{[15
]}

Jukema, J. Wouter ^{[16
]}

Kimura, Takeshi ^{[17
,679
]}

Kiss, Robert Gabor ^{[18
,51
]}

Lecorps, Guillaume ^{[14
]}

Mahaffey, Kenneth W. ^{[15
]}

Moryusef, Angele ^{[11
]}

Pordy, Robert ^{[19
]}

Roe, Matthew T. ^{[20
,21
,84
,94
]}

Tricoci, Pierluigi ^{[21
,94
]}

Xavier, Denis ^{[22
,23
,24
,25
,52
]}

Zeiher, Andreas M. ^{[26
]}

Steg, Gabriel ^{[27
,28
,29
]}

Schwartz, Gregory G. ^{[3
]}

Steg, Ph. Gabriel ^{[475
]}

Bhatt, Deepak L. ^{[5
,6
]}

Bittner, Vera A. ^{[7
]}

Diaz, Rafael ^{[10
,30
,1405
]}

Goodman, Shaun G. ^{[12
,13
]}

Harrington, Robert A. ^{[15
]}

Jukema, J. Wouter ^{[16
]}

Szarek, Michael ^{[1
,1411
]}

Zeiher, Andreas M. ^{[26
]}

Tricoci, Pierluigi ^{[21
,94
]}

Roe, Matthew T. ^{[20
,21
,84
,94
]}

Mahaffey, Kenneth W. ^{[15
]}

Edelberg, Jay M. ^{[11
]}

Hanotin, Corinne ^{[14
]}

Lecorps, Guillaume ^{[14
]}

Moryusef, Angele ^{[11
]}

Pordy, Robert ^{[19
]}

Sasiela, William J.

Tamby, Jean-Francois

Aylward, Philip E. ^{[31
,160
]}

Drexel, Heinz ^{[32
,180
]}

Sinnaeve, Peter ^{[33
,189
,1408
]}

Dilic, Mirza ^{[34
]}

Gotcheva, Nina N. ^{[35
,263
]}

Goodman, Shaun G. ^{[12
,13
]}

Prieto, Juan-Carlos ^{[36
]}

机构：

[1] SUNY, Downstate Sch Publ Hlth, Brooklyn, NY USA

[2] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand

[3] Univ Colorado, Div Cardiol, Sch Med, Aurora, CO USA

[4] Amphia Ziekenhuis Molengracht, Breda, Netherlands

[5] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[6] Harvard Med Sch, Boston, MA USA

[7] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA

[8] Taipei Vet Gen Hosp, Gen Clin Res Ctr, Taipei, Taiwan

[9] Natl Yang Ming Univ, Taipei, Taiwan

[10] Inst Cardiovasc Rosario, Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina

[11] Sanofi, Bridgewater, MA USA

[12] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada

[13] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[14] Sanofi, Paris, France

[15] Stanford Univ, Dept Med, Stanford Ctr Clin Res, Stanford, CA 94305 USA

[16] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands

[17] Kyoto Univ, Grad Sch Med, Kyoto, Kyoto, Japan

[18] Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

[19] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[20] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA

[21] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[22] St Johns Med Coll, Dept Pharmacol, Bangalore, Karnataka, India

[23] St Johns Med Coll, Div Clin Res, Bangalore, Karnataka, India

[24] St Johns Res Inst, Dept Pharmacol, Bangalore, Karnataka, India

[25] St Johns Res Inst, Div Clin Res, Bangalore, Karnataka, India

[26] Goethe Univ, Dept Med 3, Frankfurt, Germany

[27] Hop Bichat Claude Bernard, AP HP, Paris, France

[28] Paris Diderot Univ, Sorbonne Paris Cite, FACT, INSERM U1148, Paris, France

[29] Royal Brompton Hosp, Imperial Coll, Natl Heart & Lung Inst, London, England

[30] Estudios Cardiol Latinoamer, Rosario, Argentina

[31] Flinders Univ S Australia, South Australian Hlth & Med Res Inst, Med Ctr, Adelaide, SA, Australia

[32] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[33] UZ Leuven, Leuven, Belgium

[34] Univ Clin Ctr Sarajevo, Sarajevo, Bosnia & Herceg

[35] MHAT Nat Cardiol Hosp EAD, Sofia, Bulgaria

[36] Univ Chile, Hosp Clin, Santiago, Chile

[37] Peking Univ, First Hosp, Beijing, Peoples R China

[38] Fundac Oftalmol Santander FOSCAL, Floridablanca, Colombia

[39] Univ Zagreb, Univ Hosp Ctr Zagreb, Zagreb Sch Med, Zagreb, Croatia

[40] Univ Zagreb, Univ Ctr Zagreb, Sch Med, Zagreb, Croatia

[41] Na Homolce Hosp, Prague, Czech Republic

[42] Aarhus Univ Skejby, Aarhus, Denmark

[43] North Estonia Med Ctr, Tallinn, Estonia

[44] Heart & Lung Ctr, Div Cardiol, HUCH, Helsinki, Finland

[45] Hop Europeen Georges Pompidou, FACT, F CRIN network, Paris, France

[46] Chapidze Emergency Cardiol Ctr, Tbilisi, Georgia

[47] Univ Aachen, Aachen, Germany

[48] Univ Gen Hosp Ioannina, Ioannina, Greece

[49] Unidad Diagnost Cardiol, Clin privada, Guatemala City, Guatemala

[50] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 04期

关键词：

acute coronary syndrome; alirocumab; total events; ACUTE CORONARY SYNDROMES; STATIN THERAPY; REDUCTION;

D O I：

10.1016/j.jacc.2018.10.039

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. OBJECTIVES This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. METHODS Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. RESULTS With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. CONCLUSIONS In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS. (c) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

引用

页码：387 / 396

页数：10

共 50 条

[21] Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes The ODYSSEY OUTCOMES Trial
Bhatt, Deepak L.
Briggs, Andrew H.
Reed, Shelby D.
Annemans, Lieven
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Higuchi, Keiko
Joulain, Florence
Jukema, J. Wouter
Li, Qian H.
Mahaffey, Kenneth W.
Sanchez, Robert J.
Roe, Matthew T.
Lopes, Renato D.
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory G.
Steg, Ph. Gabriel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (18) : 2297 - 2308
[22] LP(A) AND CARDIOVASCULAR OUTCOMES: AN ANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL
Bittner, Vera
Szarek, Michael
Aylward, Philip E.
Bhatt, Deepak L.
Diaz, Rafael
Fras, Zlatko
Goodman, Shaun
Hanotin, Corinne
Harrington, Robert
Jukema, J. W.
Loizeau, Virginie
Moriarty, Patrick
Moryusef, Angele
Pordy, Robert
Roe, Matthew T.
Sinnaeve, Peter
White, Harvey D.
Zahger, Doron
Zeiher, Andreas
Steg, Ph G.
Schwartz, Gregory
ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 24 - 25
[23] Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Tunon, Jose
Steg, Philippe Gabriel
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Kim, Yong-Un
Li, Qian H.
Mueller, Christian
Parkhomenko, Alexander
Pordy, Robert
Sritara, Piyamitr
Szarek, Michael
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory G.
EUROPEAN HEART JOURNAL, 2020, 41 (42) : 4114 - 4123
[24] ASSOCIATION OF FATAL AND NONFATAL CARDIOVASCULAR OUTCOMES WITH 24 HOUR MEAN ARTERIAL PRESSURE
Melgarejo, Jesus
Yang, Wen-Yi
Thijs, Lutgarde
Li, Yan
Asayama, Kei
Hansen, Tine
Kikuya, Masahiro
Ohkubo, Takayoshi
Dolan, Eamon
Stolarz-Skrzypek, Katarzyna
Huang, Qi-Fang
Tikhonoff, Valerie
Malyutina, Sofia
Casiglia, Edoardo
Lind, Lars
Sandoya, Edgardo
Filipovsky, Jan
Gilis-Malinowska, Natasza
Narkiewicz, Krzysztof
Kawecka-Jaszcz, Kalina
Boggia, Jose
Wang, Ji-Guang
Imai, Yutaka
Vanassche, Thomas
Verhamme, Peter
Janssens, Stefan
Brien, Eoin O.
Maestre, Gladys E.
Staessen, Jan A.
Zhang, Zhen-Yu
JOURNAL OF HYPERTENSION, 2021, 39 : E88 - E88
[25] Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes-Prespecified Analyses of ODYSSEY OUTCOMES
Ray, Kausik K.
Colhoun, Helen
Szarek, Michael
Baccara-Dinet, Marie
Bhatt, Deepak L.
Bittner, Vera
Budaj, Andrzej J.
Diaz, Rafael, Sr.
Goodman, Shaun G.
Hanotin, Corinne G.
Jukema, J. Wouter
Loizeau, Virginie
Lopes, Renato D.
Moryusef, Angele
Pordy, Robert
Ristic, Arsen D.
Roe, Matthew
Tunon, Jose
White, Harvey D.
Schwartz, Gregory G.
Steg, Philippe G.
DIABETES, 2018, 67
[26] Nonfatal and fatal cardiovascular disease events in CPAP compliant obstructive sleep apnea patients
Minna Myllylä
Anna Hammais
Mikhail Stepanov
Ulla Anttalainen
Tarja Saaresranta
Tarja Laitinen
Sleep and Breathing, 2019, 23 : 1209 - 1217
[27] Relation of body mass index to fatal and nonfatal cardiovascular events after cardiac rehabilitation
Sierra-Johnson, J
Wright, SR
Lopez-Jimenez, F
Allison, TG
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (02): : 211 - 214
[28] Nonfatal and fatal cardiovascular disease events in CPAP compliant obstructive sleep apnea patients
Myllyla, Minna
Hammais, Anna
Stepanov, Mikhail
Anttalainen, Ulla
Saaresranta, Tarja
Laitinen, Tarja
SLEEP AND BREATHING, 2019, 23 (04) : 1209 - 1217
[29] Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ray, Kausik K.
Colhoun, Helen M.
Szarek, Michael
Baccara-Dinet, Marie
Bhatt, Deepak L.
Bittner, Vera A.
Budaj, Andrzej J.
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Loizeau, Virginie
Lopes, Renato D.
Moryusef, Angele
Murin, Jan
Pordy, Robert
Ristic, Arsen D.
Roe, Matthew T.
Tunon, Jose
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory S.
Steg, Philippe Gabriel
Schwartz, Gregory G.
Steg, Ph. Gabriel
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Jukema, J. Wouter
Szarek, Michael
Zeiher, Andreas M.
Tricoci, Pierluigi
Roe, Matthew T.
Mahaffey, Kenneth W.
Edelberg, Jay M.
Hanotin, Corinne
Lecorps, Guillaume
Moryusef, Angele
Pordy, Robert
Sasiela, William J.
Tamby, Jean-Francois
Aylward, Philip E.
Drexel, Heinz
Sinnaeve, Peter
Dilic, Mirza
Gotcheva, Nina N.
Goodman, Shaun G.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : 618 - 628
[30] Relation of Lipoprotein(a) Levels to Incident Diabetes and Modification by Alirocumab Treatment: An Analysis of the Odyssey Outcomes Trial
Schwartz, Gregory G.
Szarek, Michael
Baccara-Dinet, Marie
Bittner, Vera A.
Bhatt, Deepak L.
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Jukema, J. Wouter W.
Manvelian, Garen
Pordy, Robert
White, Harvey D.
Zeiher, Andreas M.
Steg, Philippe G.
CIRCULATION, 2020, 142

← 1 2 3 4 5 →